Description
Research Peptide≥99% HPLC StandardShips from Canada
Overview
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as an agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a). It was developed as a highly selective secretagogue and is supplied as a stable lyophilized peptide.
In research it is studied as a tool for stimulating growth-hormone (GH) release through the ghrelin-receptor pathway, distinct from growth-hormone-releasing hormone (GHRH). Its defining research interest is selectivity: unlike earlier peptides in this class, it releases GH in model systems with little effect on cortisol, ACTH, or prolactin, making it useful for isolating GHS-R1a signalling. It is offered strictly as a research material, and the studies cited below describe preclinical findings only.
Mechanisms of interest in research
Ghrelin / GHS-R1a receptor agonism
The growth-hormone-secretagogue receptor GHS-R1a, the target of the hormone ghrelin, drives pulsatile GH release from the pituitary. Ipamorelin binds this receptor as an agonist, and in pituitary-cell and animal models it stimulates GH secretion, which is why it is used to probe ghrelin-receptor signalling independently of GHRH.
Selectivity for GH release
A central research feature of ipamorelin is its selectivity: in model systems it releases GH without the increases in ACTH, cortisol or prolactin seen with less selective secretagogues, even at high relative doses. This clean profile is the main reason it is favoured as a research probe of the GH axis.
Growth-hormone axis and downstream endpoints
Sustained GH signalling feeds into IGF-1 production and downstream tissue endpoints such as bone. Ipamorelin has therefore been studied in longer-term animal models examining body weight and bone mineral content as readouts of GH-axis activation.
Specifications
Certificate of Analysis
Representative testing for Ipamorelin, part of our ongoing quality program. Testing is conducted on Vylara-supplied samples of this compound.
Selected Research
The following peer-reviewed studies are provided for scientific context on this compound’s research background. They describe preclinical and in-vitro findings only and are not claims about this product.
In rat pituitary cells and in rats and swine, ipamorelin selectively released growth hormone without affecting ACTH or cortisol even at 200-fold the GH ED50, which the authors described as GHRH-like selectivity for a GHS-receptor agonist.
Raun K, et al. Eur J Endocrinol. PMID: 9849822
In adult female rats, ipamorelin (and GH-releasing peptide-6) increased body weight and total bone mineral content, though the gain in bone mineral content was no longer significant once corrected for the greater body weight.
Svensson J, et al. J Endocrinol. PMID: 10828840
This product is intended exclusively for in-vitro laboratory research. It is not a drug, food, dietary supplement, or cosmetic, and it is not intended for human or veterinary diagnostic, therapeutic, or recreational use.
